“…[27] Recently, several case reports on the use of aripiprazole in the treatment of DD have been published. [28][29] [30][31] [32] Aripiprazole, a third-generation antipsychotic (TGA) that differs from SGA for its partial D2 agonist properties, is effective and well-tolerated in the treatment of psychosis in schizophrenia spectrum disorders as well as in other mental illnesses with predominant hallucinations, including obsessive-compulsive disorder, olfactory reference syndrome. [1] [33] Given the poor response to pharmacological treatment of DD, evidence-based treatment is needed.…”